Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure.

"We are pleased that the FDA has approved the protocol for this Phase III study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer," stated Martin D. Phillips, M.D., Chief Medical Officer of Morphotek. "Physicians and patients do not have many good choices for treating ovarian cancer at this stage, and we are hopeful that some day farletuzumab may provide an option for ovarian cancer patients and their caregivers."

Morphotek is currently concluding a Phase II trial with farletuzumab as a single-agent and in combination with standard-of-care chemotherapy (carboplatin and taxane) in platinum-sensitive ovarian cancer patients experiencing a first relapse of their disease. The trial was designed to measure objective rate of response, and to compare the length of a patient's second remission with her first remission. Interim results from the study demonstrated an encouraging rate of durable objective response in patients on combination therapy. These findings prompted pursuit of a definitive pivotal study to evaluate the capacity of farletuzumab to benefit patients with ovarian cancer in a rigorously controlled manner.

The Phase III study, the design of which was agreed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, plac
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 First Choice Emergency Room ... in the United States, announced that it is expanding ... Green Valley Ranch facility. , “I am pleased ... the highest quality emergency medical care to Denver residents ... said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:5/28/2015)... CA (PRWEB) May 28, 2015 Although ... they are stuck with their slow metabolism for life, ... weight, this is not true. There are methods to ... increase their advertisements for low-carbohydrate, low-fat and no-fat foods, ... are eating healthy, many times the foods contain hidden ...
(Date:5/28/2015)... Orem, UT—Dymicron, Inc., (dymicron.com) confirmed the ... unique Triadyme-C cervical total disc replacement device. The two ... Smith at the American Institute of Minimally Invasive Surgery ... well to the implantation of the Dymicron devices,” said ... and Chief of Neurosurgery for the University Medical Center, ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Dallas ... updated version of his patient education website ... redesign allows patients to readily access current educational ... dysfunction treatment, male urinary incontinence, prostate cancer treatment, ... of this website is to educate patients on ...
(Date:5/28/2015)... Provo, Utah (PRWEB) May 28, 2015 ... corporate training, is pleased to announce that Career Step ... speaker in a June 4 webinar presented by ICD10monitor ... Clinical Documentation at HRS. Mr. Hodgson and Ms. Carr ... training for a successful ICD-10 transition. , “We have ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room to Open New Facility in Denver, Colorado 2Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 2Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 3Health News:As Part of their Comprehensive Weight Loss Program, Diet Doc Now Teaches Patients how to Identify Hidden Carbohydrates for Safe, Fast and Long Term Weight Loss Success 4Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Mark Allen MD, Dallas Urologist, Launches Updated Patient Education Website With a Focus on Prostate Cancer and Erectile Dysfunction Treatment 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3
... Autism Association Push,for Services Worldwide, BETHESDA, Md., ... April 2 as World Autism Awareness Day. To ... the World Autism,Organization and the Co-Chairs of the ... Rep. Chris Smith and Rep.,Mike Doyle, will hold ...
... pharmaceutical industry currently underway will increase in the next ... at the National Institutes of Health (NIH) who is ... , According to Christopher Austin, M.D., director ... and academia welcome more cooperation in drug discovery to ...
... CHICAGO, Ill. (April 1, 2008) A new bioabsorbable ... threading catheters into the body during diagnostic angiography and ... to get up and walk around far sooner than ... addition, there were no access site complications at 30 ...
... Include Economic Development Stimulus ... as Means to Address Social Issues, DETROIT, ... today announced a total of $50,000 in grants to,the Detroit ... for innovative community programs,demonstrating a broader scope for the charitable ...
... Top Five Global Market ... ... (UL), a world leader of product safety testing services,announced today that ... registrar in independent third party management,system certification services headquartered in Frankfurt ...
... ... With U.S. Presence, AMSTERDAM, The Netherlands, ... evolving field of cancer molecular diagnostics,today announced the appointment of Richard ... medical officer (CMO). Dr. Bender, who,will report directly to Chief Executive ...
Cached Medicine News:Health News:Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day 2Health News:Reps. Smith and Doyle, Autism Society of America Push Landmark Legislation on World Autism Awareness Day 3Health News:Business of drug development on verge of great change 2Health News:ExoSeal vascular plug gets good reviews in ECLIPSE study 2Health News:Ilitch Charities Invests $50,000 in Innovative Community Programs 2Health News:Ilitch Charities Invests $50,000 in Innovative Community Programs 3Health News:Underwriters Laboratories' Management System Registration Business to Merge With Germany's DQS 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 2Health News:Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer 3
(Date:5/27/2015)... 2015 OpportunityAnalyzer: Cushing,s Syndrome - Opportunity ... GlobalData estimates that the 2013 sales for the ... across the 6MM covered in this report. Pharmaceutical ... time, and financial resources in the CS field, ... (R&D) strategies. One notable example is the fact ...
(Date:5/27/2015)... May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering. ... issues pertaining to the US NAT laboratory ... demographic, social and technological trends with significant ...
(Date:5/27/2015)... Research and Markets ( ... the  "US Cancer Vaccine Market Outlook 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,Cancer vaccines ... categories of prophylactic (preventive) and therapeutic (treatment) ... both of these groups have been marketed ...
Breaking Medicine Technology:OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4United States Nucleic Acid Testing Market Strategies 2015-2020 2US Cancer Vaccine Market Outlook 2020 2US Cancer Vaccine Market Outlook 2020 3
... - Termination of Parkinson,s Disease Clinical Development and Focus ... Neuropathic Pain and Epilepsy ... is a first-in-class,orally administered, highly selective non-competitive AMPA-type glutamate,receptor ... disease, neuropathic pain, epilepsy, multiple,sclerosis and migraine prophylaxis., ...
... Napo,Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased ... Phase 2 trial for CRO-ID,(crofelemer for the treatment ... Glenmark Pharmaceuticals Limited (BSE: Glenmark). The,primary endpoints of ... frequency and stool consistency; additional endpoints followed,include degree ...
Cached Medicine Technology:Status of the E2007 (perampanel) Development Program 2Status of the E2007 (perampanel) Development Program 3Status of the E2007 (perampanel) Development Program 4Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 2Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 3Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 4Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea 5
...
...
...
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
Medicine Products: